ACW – What's the Outlook?Actinogen Medical (ASX:ACW) is advancing its lead candidate, Xanamem, targeting neurological conditions linked to elevated cortisol levels. The company is currently conducting the XanaMIA Phase 2b/3 trial for Alzheimer's disease, with interim results anticipated in Q3 2025 and final outcomes expected by Q4 2026 .Recent forecasts suggest a potential short-term price range between $0.0170 and $0.0195 . While the stock has experienced a decline over the past year, the upcoming trial results could be a significant catalyst.Given these developments, is ACW a speculative opportunity worth considering, or is it prudent to wait for more concrete data?
ACW – What's the Outlook?Actinogen Medical (ASX:ACW) is...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
0.002(10.0%) |
Mkt cap ! $69.89M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.2¢ | 2.0¢ | $71.12K | 3.292M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1264000 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 3890884 | 4 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| ACW (ASX) Chart |